Quercetin In The Treatment Of SARS-COV 2

Properties

• Anti-oxidant, vascular protector
• Inhibition of platelet aggregation, vasorelaxant , arterial relaxant
• Anti-hypertensive , especially by certain derivatives (quercetin-3-glucuronic acid)
• Nephroprotective in rats, protects against the nephrotoxicity of gentamicin
• Anticancer , with immunostimulatory activity and inducer of apoptosis, with activity on the shock proteins HSP (heat shock proteins) hsp27 and hsp70
• Antitumor activity against prostate cancer and certain breast cancer cells
• Prevention of cardiac toxicity from doxorubicin, with resveratrol
• Protection against gastric inflammation associated with Helicobacter pylori infection by activity on MAPK, BCL-2, BAX.
• Increases the antitoxic activity of the liver
• Pancreatic lipase inhibitor, potential action in weight gain
• Anti-inflammatory
• Anti-allergic, inhibition of mast cell degranulation, with a preventive effect, reduction of inflammation linked to eosinophils (such as isoquercitrin regulates the Th1 / Th2 balance
• Antiviral (dose-dependent reduction of infectivity, decreases intracellular replication)
• Inhibition of rhinovirus replication
• Influenza prophylaxis by quercetin or its derivatives (quercetin-3-O-α-L-rhamnopyranoside), opposes the pro-oxidant effects induced by the influenza virus, antioxidant therapy could be used to prevent serious complications associated with influenza
• In vitro inhibition of the penetration of the Ebola virus by quercetin-3-O-glucoside
• Antiviral activity against Zika virus, hepatitis B virus, hepatitis C, Epstein-Barr virus EBV and antitumor against human gastric carcinoma

Inclusion criteria

• • Clinical score greater than 6

• Patients with clinical symptoms less than 5 days old.
• Men and women at least 40 years old, able and willing to give informed consent;
• Any patient over the age of 18 with a CT scan in favor of COVID-19;
• Ambulatory or hospitalized environment;
• Patient with dyspnea or with a positive gait test;
• The patient must have at least one of the following high risk criteria: 70 years or older, obesity (BMI ≥ 30 kg / m2), diabetes mellitus, uncontrolled hypertension (systolic blood pressure ≥ 150 mm Hg), respiratory disease known (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary artery disease, fever ≥ 38.4 ° C within the last 48 hours, dyspnea at the time of presentation, bicytopenia, pancytopenia or a combination of a number high neutrophils and low lymphocytes count;
• The patient is not of childbearing age, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing age and uses at least one method of contraception and preferably two complementary forms of contraception comprising a method of barrier throughout the study and for 30 days after the end of the study;
• The patient must be able and willing to comply with the requirements of this study protocol.

Exclusion criteria

• • Patient currently in shock or exhibiting hemodynamic instability;

• Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption;
• Pregnant or breastfeeding patient
• Patient with a history of allergic reaction or significant sensitivity to Nigella;
• The patient is considered by the investigator, for whatever reason, to be an unsuitable candidate for the study.